BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19901101)

  • 21. Predictive biomarkers in adult gliomas: the present and the future.
    Thomas L; Di Stefano AL; Ducray F
    Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
    Yang SH; Hong YK; Yoon SC; Kim BS; Lee YS; Lee TK; Lee KS; Jeun SS; Kim MC; Park CK
    Oncol Rep; 2007 Jun; 17(6):1359-64. PubMed ID: 17487391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic glioma.
    Morris PG; Lassman AB
    Nat Rev Clin Oncol; 2010 Aug; 7(8):428-30. PubMed ID: 20668479
    [No Abstract]   [Full Text] [Related]  

  • 24. Temozolomide and MGMT forever?
    Weller M
    Neuro Oncol; 2010 Mar; 12(3):219-20. PubMed ID: 20167809
    [No Abstract]   [Full Text] [Related]  

  • 25. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    Erdem-Eraslan L; Gravendeel LA; de Rooi J; Eilers PH; Idbaih A; Spliet WG; den Dunnen WF; Teepen JL; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; van den Bent MJ; French PJ
    J Clin Oncol; 2013 Jan; 31(3):328-36. PubMed ID: 23269986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
    Mokhtari K; Ducray F; Kros JM; Gorlia T; Idbaih A; Taphoorn M; Wesseling P; Hoang-Xuan K; Van den Bent M; Sanson M
    Cancer; 2011 Jul; 117(13):3014-26. PubMed ID: 21246521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
    Molnár P; Méhes G
    Magy Onkol; 2009 Mar; 53(1):33-8. PubMed ID: 19318324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
    Brada M; Stenning S; Gabe R; Thompson LC; Levy D; Rampling R; Erridge S; Saran F; Gattamaneni R; Hopkins K; Beall S; Collins VP; Lee SM
    J Clin Oncol; 2010 Oct; 28(30):4601-8. PubMed ID: 20855843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
    Sasaki H; Hirose Y; Yazaki T; Kitamura Y; Katayama M; Kimura T; Fujiwara H; Toda M; Ohira T; Yoshida K
    J Neurooncol; 2015 Aug; 124(1):127-35. PubMed ID: 26007163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
    Sutera P; Kalash R; Flickinger J; Engh J; Heron DE
    Am J Clin Oncol; 2019 Jan; 42(1):27-35. PubMed ID: 29912004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
    Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
    Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
    Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
    J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.
    van den Bent MJ; Erdem-Eraslan L; Idbaih A; de Rooi J; Eilers PH; Spliet WG; den Dunnen WF; Tijssen C; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; French PJ
    Clin Cancer Res; 2013 Oct; 19(19):5513-22. PubMed ID: 23948976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
    de Wit MC; de Bruin HG; Eijkenboom W; Sillevis Smitt PA; van den Bent MJ
    Neurology; 2004 Aug; 63(3):535-7. PubMed ID: 15304589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
    Abrunhosa-Branquinho AN; Bar-Deroma R; Collette S; Clementel E; Liu Y; Hurkmans CW; Feuvret L; Van Beek K; van den Bent M; Baumert BG; Weber DC
    Radiother Oncol; 2018 May; 127(2):292-298. PubMed ID: 29606522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of malignant glioma--quo vadis?
    Stupp R; Hottinger AF
    Onkologie; 2008 Jun; 31(6):300-2. PubMed ID: 18547969
    [No Abstract]   [Full Text] [Related]  

  • 40. Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
    Yang P; Zhang C; Cai J; You G; Wang Y; Qiu X; Li S; Wu C; Yao K; Li W; Peng X; Zhang W; Jiang T
    Oncotarget; 2016 Nov; 7(48):80091-80100. PubMed ID: 27590514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.